V. Smits

HIV-1 genotyping of the protease-reverse transcriptase and integrase genes to detect mutations that confer antiretroviral resistance.

P. van den Eede, Y. Verlinden, L. Van Wesenbeeck, 2013, Methods in molecular biology.

Resistance Mutations in Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a Wide Range of Integrase Inhibitors

K. Hertogs, Peggy Geluykens, Inge Vereycken, 2008, Journal of Virology.

Cross-Resistance Profile Determination of Two Second-Generation HIV-1 Integrase Inhibitors Using a Panel of Recombinant Viruses Derived from Raltegravir-Treated Clinical Isolates

L. Stuyver, K. Van Baelen, H. de Wolf, 2010, Antimicrobial Agents and Chemotherapy.

Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor.

K. Hertogs, M. Cummings, R. Clayton, 2011, Antiviral research.

Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles.

Dominique Schols, Kurt Hertogs, K. Hertogs, 2010, Virology.